Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Report Description
Tuberculosis is a deadly infectious disease that affects the lungs. Among diseases, tuberculosis is the second largest cause of death worldwide. Tuberculosis are broadly classified as latent tuberculosis and active tuberculosis. Globally around 10% of latent infections develop into active tuberculosis. Infections that do not show any symptoms are called latent tuberculosis. In 2015, the malady resulted in 1.8 million deaths and 10.4 million new reported cases. In 2015, in the U.S., there were 9,557 tuberculosis cases reported. Based on the statistics of Center for Disease Control and Prevention, a 1.6% increase in the number of tuberculosis cases was observed in 2015 as compared to those reported in 2014. Though there is an increase in the number of tuberculosis cases, the incidence rate per 100,000 persons has been around 3.0 since 2013.
Market Dynamics
Asia and Africa are the largest markets for tuberculosis drugs, as these regions have the highest prevalence of TB. There are many initiatives taken to control the TB increasing cases. The United Nations' Millennium Development Goals have framed various strategies to reduce TB prevalence and death rates by 2015, which can be achieved by WHO's Stop TB Strategy. According World Health Organization, in 2006, 61% out of 2.5 million new smear positive cases with DOTS, and are all the new smear cases on the year, and the treatment was successful in 85% cases. The estimated global incidence rate of tuberculosis shown decline rate by 0.6% in 2005 and 2006. In 2006, the incidence rate of tuberculosis became stable in the Europe and is declining gradually in the other WHO countries. World Health Organization has an approximation that the occurrence of tuberculosis and death rates are declining faster than the incidence rate.
Market Taxonomy
This report segments the global tuberculosis drugs market on the basis of therapy type and geography. On the basis of therapy type, the market is categorized into first line drugs, Second line drugs and combination drug therapy. Under First line drugs, the market is further segmented into drugs such as Isoninazid, Rifampicin, Ethambutol, Pryazinamide, and Strepromycin. The second line drugs are further segmented into Injectable, Fluoroquinolones, and Bacteriostatic Agents and Others. For comprehensive understanding of market dynamics, the global tuberculosis drugs market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.
Key features of the study:
• This report provides in-depth analysis of the tuberculosis drugs market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 - 2024, considering 2015 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global tuberculosis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Pfizer Inc, Lupin Laboratories Ltd, AstraZeneca Plc, Cadila Pharmaceuticals, Novartis AG, Alkem Laboratories Ltd, and Cipla Ltd.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
• The global tuberculosis drugs market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers for tuberculosis drugs, research and consulting firms, new entrants, and financial analysts
• Various strategy matrices used in analyzing the tuberculosis drugs market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
• Global Tuberculosis Drugs Market, By Therapy Type:
o First Line Drugs Therapy
o Second Line Drugs Therapy
o Combination Drugs Therapy
• Global Healthcare Biometrics Market, By Geography:
o North America
U.S.
U.S. Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Canada
Canada Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
o Europe
U.K.
U.K. Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Germany
Germany Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Italy
Italy Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
France
France Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Spain
Spain Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Russia
Russia Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Rest of Europe
Rest of Europe Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
o Asia-Pacific
China
China Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
India
India Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Japan
Japan Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
ASEAN
ASEAN Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Australia
Australia Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
South Korea
South Korea Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Rest of Asia Pacific
Rest of Asia Pacific Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
o Latin America
Brazil
Brazil Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Mexico
Mexico Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Rest of Latin America
Rest of Latin America Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
o Middle East
GCC
GCC Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Israel
Israel Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Rest of Middle East
Rest of Middle East Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
o Africa
North Africa
North Africa Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Central Africa
Central Africa Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
South Africa
South Africa Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
• Company Profiles
o Pfizer Inc *
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
o Lupin Laboratories Ltd
o AstraZeneca Plc
o Cadila Pharmaceuticals
o Novartis AG
o Alkem Laboratories Ltd
o Cipla Ltd.
"*" marked represents similar segmentation in other categories in the respective section.
